In tumor immunotherapy, successful treatment methods so far have relied on immune checkpoint inhibitors with targets such as programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4). Here, PDCD1 is linked to neoplasm.